These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38561511)

  • 41. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
    Tang L; Sun C; Liu W; Wu H; Ding C
    Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285
    [No Abstract]   [Full Text] [Related]  

  • 42. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mining and evaluation of adverse event signals for capmatinib based on the FAERS database.
    Chen X; Jiang Y; Zhu H; Tian M
    Front Pharmacol; 2024; 15():1417661. PubMed ID: 39380910
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine.
    Zhong C; Zheng Q; Zhao B; Ren T
    Expert Opin Drug Saf; 2024 Oct; ():1-11. PubMed ID: 39340205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS).
    Shi FE; Yu Z; Sun C; Gao P; Zhang H; Zhu J
    Expert Opin Drug Saf; 2024 Feb; 23(2):221-229. PubMed ID: 37554093
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.
    Yang X; Yan Y; Liu S; Wang Z; Feng X
    Front Pharmacol; 2024; 15():1376494. PubMed ID: 38846098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strong opioids-induced cardiac, neurologic, and respiratory disorders: a real-world study from 2004 to 2023 based on FAERS.
    Dai M; Dou X; Chen M; Yang J; Long J; Lin Y
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4105-4121. PubMed ID: 38032491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database.
    Hu Y; Du Y; Qiu Z; Zhu C; Wang J; Liang T; Liu T; Da M
    Front Pharmacol; 2024; 15():1399998. PubMed ID: 39108741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical safety of daridorexant in insomnia treatment: Analysis of FDA adverse event reports.
    Wang Q; Zhou Q; Du Z; Lu R; Jiang Y; Zhu H
    J Affect Disord; 2024 Oct; 362():552-559. PubMed ID: 39019232
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.
    Altebainawi AF; Alfaraj LA; Alharbi AA; Alkhuraisi FF; Alshammari TM
    Ther Adv Drug Saf; 2023; 14():20420986231154075. PubMed ID: 36875514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
    Yang Z; Tang K; Chen J
    Expert Opin Drug Saf; 2024 Oct; ():1-8. PubMed ID: 39325652
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database.
    Jiang Y; Du Z; Shen Y; Zhou Q; Zhu H
    Eur Arch Psychiatry Clin Neurosci; 2023 Dec; ():. PubMed ID: 38103077
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blind Spots in Therapy: Unveiling Drug-Induced Angle-Closure Glaucoma Through a National Analysis.
    Aftab OM; Khan H; Khouri AS
    Ophthalmol Glaucoma; 2024; 7(5):485-490. PubMed ID: 38679326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis.
    Zhang W; Xu Z; Shu Y; Shu S; Zhang Q
    Pharmaceuticals (Basel); 2024 Aug; 17(8):. PubMed ID: 39204132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
    Li Z; Guo C; Liu X; Qiu Z; Zhang R
    Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
    [No Abstract]   [Full Text] [Related]  

  • 58. Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.
    Xiong S; Gou R; Liang X; Wu H; Qin S; Li B; Luo C; Chen J
    Diabetes Ther; 2024 Aug; 15(8):1717-1733. PubMed ID: 38776037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Data mining of the public version of the FDA Adverse Event Reporting System.
    Sakaeda T; Tamon A; Kadoyama K; Okuno Y
    Int J Med Sci; 2013; 10(7):796-803. PubMed ID: 23794943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system.
    Nicholls C; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(1):63-73. PubMed ID: 35491805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.